Category: Psychedelics
-
![Revive Therapeutics (RVV.C) CEO Michael Frank likes the stock, buys the dip]()
Revive Therapeutics (RVV.C) CEO Michael Frank likes the stock, buys the dip
+135k shares in a downturn, my man The psychedelics sector is down bad this week. Just look at the psychedelics ETF PSYK.NE. It’s not an alarm or anything, things have been running pretty nicely the past couple of quarters and it was probably time for a correction. Any time a sector emerges this quickly there…
-
Pure Extracts (PULL.C) looks to level up with dealers license application
At a time when many cannabis companies are enjoying bursts of investor interest, management at BC-based extractor Pure Extracts (PULL.C) must be getting frustrated as they roll out new contracts, new manufacturing lines, and advance in their pursuit of licensing that would allow them to break out into psychedelics. In essence, they’re hitting all the…
-
![How Field Trip (FTRP.CN) is scaling its ketamine therapy operations following a giant raise]()
How Field Trip (FTRP.CN) is scaling its ketamine therapy operations following a giant raise
Supersized bought deal Field Trip (FTRP.CN) announced on Friday that it raised a whopping $95.3M CAD through a bought deal. The deal was originally for proceeds of $50M CAD but was later upsized to $82.9M CAD. It was priced at $6.50 CAD per share, adding 12.8M shares to the pool, bringing the number of shares…
-
Delic Holdings (DELC.C) acquires licensed psilocybin/cannabis lab, is doing legal shroom business
For a year, naysayers have dismissed the early stage shroom boom as being a pumpy bunch of pubco RTOs that won’t be able to do business legally for years. To be fair, there’s some basis to that dismissal. But only some. We’ve also been talking about how Delic Holdings (DELC.C) was an all-star team of…
-
![Atai and Psybio: A closer look at two very different upcoming psychedelics IPO’s for 2021]()
Atai and Psybio: A closer look at two very different upcoming psychedelics IPO’s for 2021
IPO’s come in all shapes and sizes, some are giants with billionaire support, and others don’t have a pitch deck readily available. Investors get giddy with news of IPO’s as it signals a chance to get in early. It’s important to note that ‘getting in early’ isn’t a guarantee in an IPO, relatively speaking. Take…
-
![Compass Pathways (CMPS.Q) is rubbing investors the wrong way, again]()
Compass Pathways (CMPS.Q) is rubbing investors the wrong way, again
Cut the kumbaya shit Throwing the words profit and psychedelic drugs into a sentence would have lead to awkward and confused looks 5 years ago. But we have come a long way, and in that process, questions have arisen like: how do money and psychedelics mix? Psychedelic medicine advocates who have never been around the…
-
Canntab (PILL.C) yeets another patent for hard-pressed, long release cannabis pills
I’ve made no secret of the fact that the Canadian cannabis market frequently annoys the hell out of me. What I want is for it to be a mature space that more and more adults are making use of, and that is free to innovate, free to be excellent, free to market itself properly, and…
-
![Delic Holdings (DELC.C) to acquire industry leading ketamine clinics as plan becomes clearer]()
Delic Holdings (DELC.C) to acquire industry leading ketamine clinics as plan becomes clearer
Regular readers with an interest in psychedelics will know we recently started talking to a company called Delic Holdings (DELC.C), and that it was a company coming to the market, not claiming it had the answers to profitability in a competitive space, or that it would lead the world in this or that but, rather,…
-
![Canntab Therapeutics (PILL.C): The Canadian weed sector is struggling, but new consumer products have room to scale]()
Canntab Therapeutics (PILL.C): The Canadian weed sector is struggling, but new consumer products have room to scale
If we’re honest about it – if we’re REALLY honest about it – Canada has fumbled its advantage in the cannabis sector. First to market, first to raise hundreds of millions in financing, first to legalize, first to recreationalize (not a word but I’m on a roll), and it’s all really been for naught. In…
-
Does Core One Labs (COOL.C) have a solution for psilocybin’s dosing problem?
Core One’s objective in developing the psilocybin thinstrips is to assist with the delivery of revolutionary psychedelic treatment methods to address mental health conditions such as depression, anxiety and addictions.
